With approximately 200.

Abbott’s XIENCE V Approved in Japan – Second Largest Medication Eluting Stent Market Worldwide Abbott announced that the Japanese Ministry of Health, Labor and Welfare has approved its XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease tadalafil . Japan may be the second largest medication eluting stent market in the global globe after the United States, with approximately 200, 000 stent procedures performed each full year. The company plans to release XIENCE V in Japan in the upcoming weeks, following last reimbursement authorization immediately. With today’s approval, physicians in Japan will will have access to a next-generation medication eluting stent that provides outstanding simplicity and excellent clinical efficiency and basic safety.